Premium
Case‐control study in non‐insulin‐dependent diabetes mellitus (NIDDM) subjects treated with acarbose
Author(s) -
Guagnano Maria Teresa,
Loggia Fulvio Della,
PacePalitti Valeria,
Spoltore Rosa,
Capitanio Rossella,
Sensi Sergio
Publication year - 1998
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/(sici)1098-2299(199802)43:2<128::aid-ddr6>3.0.co;2-m
Subject(s) - acarbose , postprandial , medicine , diabetes mellitus , hemoglobin , insulin , endocrinology , gastroenterology
Newer therapeutic approaches are being employed for the treatment of diabetes mellitus, and among these, acarbose, an α‐glucosidase inhibitor, has proven effective in lowering postprandial blood glucose levels and glycosylated hemoglobin. The aim of the present study was to evaluate the effects of acarbose in non‐insulin‐dependent diabetes mellitus (NIDDM) patients. Thirty‐four NIDDM outpatients were enrolled who were followed at our Diabetic Clinic of the Internal Medicine Institute—Chieti University. They were randomized according to a case‐control study protocol. The observation period lasted 3 months and tests were performed on the first, second, and third month. Group 1 patients received acarbose 50 mg, three times a day for the first month and 100 mg three times a day for the remaining 2 months. Subjects treated with acarbose showed a reduction of 22% in blood glucose (BG) ( P < 0.001) and of glycosylated hemoglobin (HbA1c) (17%‐ P < 0.001) at the end of the study, while the control subjects presented only a slight reduction (10%) of BG ( P < 0.05). After case‐control analysis, BG and HbA1c were significantly lower in the case subjects ( P < 0.005 and P < 0.02, respectively). In patients with NIDDM, acarbose is a well‐tolerated drug with short‐term effects mainly on blood glucose levels, while the lowering effects on HbA1c require longer observation periods. Drug Dev. Res. 43:128–131, 1998. © 1998 Wiley‐Liss, Inc.